CalciMedica to Present at Two Healthcare Investment Conferences

CalciMedica Inc., based in La Jolla, California, is a clinical-stage biopharmaceutical firm dedicated to the development of innovative therapies targeting calcium release-activated calcium (CRAC) channels for the treatment of both acute and chronic inflammatory and immunologic conditions. On July 8, 2024, the company announced that Rachel Leheny, Ph.D., its Chief Executive Officer, will be presenting at two significant healthcare investment conferences.

The first event is the H.C. Wainwright 3rd Annual Kidney Virtual Conference, scheduled for Monday, July 15, 2024, at 11:00 am ET/8:00 am PT. The second is the JonesTrading Healthcare Seaside Summit, also on Monday, July 15, 2024, at 1:15 pm ET/10:15 am PT. Both presentations will be available via live webcasts, accessible through the "Upcoming Events" section on CalciMedica's Investor Relations website. Additionally, recordings of these webcasts will remain on the company's website for a duration of 90 days.

CalciMedica is at the forefront of utilizing CRAC channel inhibition to modulate immune responses and prevent tissue cell damage. This innovative approach has the potential to offer significant therapeutic benefits for severe inflammatory and immunologic disorders, many of which currently lack approved treatments.

The company’s leading product candidate, Auxora™, has shown promising and consistent results in various clinical trials. These trials include a Phase 2b study (CARPO – NCT04681066) for patients with acute pancreatitis (AP) and systemic inflammatory response syndrome (SIRS), which has already reported topline data. Another completed Phase 2b trial (CARDEA – NCT04345614) focused on patients with COVID-19 pneumonia. CalciMedica continues to support the ongoing Phase 1/2 AIPT study (CRSPA – NCT04195347), with results anticipated in 2025. Additionally, the company has initiated a Phase 2 study (KOURAGE – NCT06374797) targeting acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), with data expected in 2025.

Founded by scientists from Torrey Pines Therapeutics and Harvard's CBR Institute for Biomedical Research, CalciMedica is firmly rooted in scientific innovation and research excellence. The company's goal is to develop CRAC channel inhibitors that can provide new therapeutic options for patients suffering from severe and life-threatening inflammatory and immunologic diseases.

In summary, CalciMedica Inc. continues to make strides in the biopharmaceutical arena with its focus on CRAC channel inhibition therapies. The upcoming presentations by CEO Rachel Leheny, Ph.D., at two notable healthcare investment conferences are set to highlight the progress and potential of their pioneering therapeutic approaches. With a strong foundation in innovative research and ongoing clinical trials, CalciMedica is poised to advance its mission of addressing unmet medical needs in the realm of inflammatory and immunologic diseases.